Level C· Early human research exploring benefits
Potential drawbacks in cell-assisted lipotransfer: A systematic review of existing reports
Huang S., Zhao W., Wang Z., Chang P.
Reviewed 57 CAL studies focusing on drawbacks and risks such as graft liquefaction/resorption and the absence of standardised guidelines.
Level C· Early human research exploring benefitsEvidence level of this study
Early human evidence such as case series or small samples is exploring possible benefits.
- Level A · Stronger Clinical Evidence
- Level B · Emerging clinical evidence with positive signals
- Level C · Early human research exploring benefits
- Level D · Scientific groundwork from lab and animal studies
- Emerging · Emerging topic under active research
- Study type
- Systematic Review
- Journal
- Molecular Medicine Reports (2016)
- Country
- China
- Sample size
- —
- Follow-up
- Not applicable (literature review)
- PMID
- 26677061
- DOI
- 10.3892/mmr.2015.4682
What was studied
Drawbacks, risks and regulatory gaps in the clinical use of CAL.
Methods
- • Reviewed 57 publications, of which seven described actual clinical application.
Key findings
- • Clinical use was concentrated in breast augmentation and soft-tissue augmentation.
- • The authors called for clear criteria and guidelines before widespread use.
Limitations
- • Narrative-style review without quantitative analysis.
- • 2016 data may be partly outdated.
What this study does not prove
- • This study does not prove SVF is an approved treatment or a replacement for standard care.
- • Limited follow-up cannot indicate long-term outcomes.
Clinical interpretation
A risk-focused counterweight to studies that report only positive outcomes.
Evidence level: Early human research exploring benefits